文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA-11 PET/MRI在根治性前列腺切除术后复发性前列腺癌检测中的临床性能

Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-10-14

回顾性分析56例根治性前列腺切除术后生化复发患者,行68Ga-PSMA-11 PET/MRI,三位读者判读。总体检出率78.6%,PSA<0.2 ng/mL组检出4/9例(44.4%),PSA 0.2–<0.5 ng/mL组检出8/11例(72.7%),PSA<0.5 ng/mL患者中5/20例为盆腔外病变。读者间一致性优秀(κ=0.796,CI 0.645–0.947)。

要点

  • 68Ga-PSMA-11 PET/MRI在PSA<0.5 ng/mL的生化复发患者中仍具有较高检出率。
  • PSA<0.5 ng/mL患者中,5/20例(25%)可定位盆腔外病变,仅10%见局部复发。
  • 读者间对癌症检出的一致性优秀,κ=0.796(CI 0.645–0.947)。

主要发现

  • 56例中44例(78.6%)检出PSMA阳性病变。
  • PSA<0.2 ng/mL的9例中4例(44.4%)检出可疑病变:2例盆腔淋巴结、1例腹主动脉旁淋巴结、2例骨转移。
  • PSA 0.2–<0.5 ng/mL的11例中8例(72.7%)检出可疑病变:2例局部复发、6例淋巴结、1例骨转移。
  • PSA<0.5 ng/mL的20例中5例为盆腔外病变。
  • PSA 0.5–<2.0 ng/mL的15例中12例(80.0%)检出可疑病变:4例局部复发、9例淋巴结、4例骨转移。

关键数值与推荐

  • 检出率:PSA<0.2 ng/mL组44.4%(4/9),PSA 0.2–<0.5 ng/mL组72.7%(8/11),PSA 0.5–<2.0 ng/mL组80.0%(12/15),PSA>2.0 ng/mL组95.2%(20/21)。
  • 读者间一致性Fleiss κ=0.796(CI 0.645–0.947)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Sensitive visualization of recurrent prostate cancer foci is a challenge in patients with early biochemical recurrence (EBR). The recently established 68Ga-PSMA-11 PET/CT has significantly improved the detection rate with published values of up to 55% for patients with a serum PSA concentration between 0.2-0.5 ng/mL. The increased soft tissue contrast in the pelvis using simultaneous 68Ga-PSMA-11 PET/MRI might further improve the detection rate in patients with EBR and low PSA values over PET/CT. METHODS: We retrospectively analyzed a cohort of 56 consecutive patients who underwent a 68Ga-PSMA-11 PET/MRI for biochemical recurrence in our institution between April and December 2016 with three readers. Median PSA level was 0.99 ng/mL (interquartile range: 3.1 ng/mL). Detection of PSMA-positive lesions within the prostate fossa, local and distant lymph nodes, bones, or visceral organs was recorded. Agreement among observers was evaluated with Fleiss's kappa (k). RESULTS: Overall, in 44 of 56 patients (78.6%) PSMA-positive lesions were detected. In four of nine patients (44.4%) with a PSA < 0.2 ng/mL, suspicious lesions were detected (two pelvic and one paraaortic lymph nodes, and two bone metastases). In eight of 11 patients (72.7%) with a PSA between 0.2 and < 0.5 ng/mL, suspicious lesions were detected (two local recurrences, six lymph nodes, and one bone metastasis). Five out of 20 patients with a PSA < 0.5 ng/mL had extrapelvic disease. In 12 of 15 patients (80.0%) with a PSA between 0.5 and < 2.0 ng/mL, suspicious lesions were detected (four local recurrences, nine lymph nodes, and four bone metastases). In 20 of 21 patients (95.2%) with a PSA >2.0 ng/mL, suspicious lesions were detected. The overall interreader agreement for cancer detection was excellent (κ = 0.796, CI 0.645-0.947). CONCLUSIONS: Our data show that 68Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate cancer even at very low PSA levels <0.5 ng/mL. Furthermore, even at those low levels extrapelvic disease can be localized in 25% of the cases and local recurrence alone is seen only in 10%.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kranzbühler B, Nagel H, Becker AS, et al. Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2017. PMID: 29032394. doi:10.1007/s00259-017-3850-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。